%0 Journal Article
%A Krech, Maja
%A Muench, Amos
%A Teichmann, Daniel
%A Kuzman, Peter
%A Suwala, Abigail K
%A Ippen, Franziska M
%A Müther, Michael
%A Weber, Katharina
%A Wenger-Alakmeh, Katharina
%A Onken, Julia
%A Vajkoczy, Peter
%A Behling, Felix
%A May, Sven-Axel
%A Ntoulias, Georgios
%A Krauss, Joachim K
%A Atallah, Oday
%A Esmaeilzadeh, Majid
%A Mueller, Wolf C
%A Heppner, Frank L
%A Radbruch, Helena
%A Dittmayer, Carsten
%A Stenzel, Werner
%A Koch, Arend
%A Capper, David
%A Kaul, David
%A Paulus, Werner
%A Plate, Karl H
%A Steinbach, Joachim P
%A Czabanka, Markus
%A Beschorner, Rudi
%A von Deimling, Andreas
%A Bockmayr, Michael
%A Neumann, Julia E
%A Brandner, Sebastian
%A Krieger, Teresa
%A Hartmann, Christian
%A Thomas, Christian
%A Schweizer, Leonille
%T Outcome-associated factors in a molecularly defined cohort of central neurocytoma.
%J Acta neuropathologica
%V 149
%N 1
%@ 0001-6322
%C Heidelberg
%I Springer
%M DKFZ-2025-01202
%P 61
%D 2025
%X Central neurocytomas (CN) are intraventricular brain tumors predominantly occurring in young adults. Although prognosis is usually favorable, tumor recurrence is common, particularly following subtotal resection (STR). Currently, the risk of progression is evaluated using atypical features and an elevated Ki67 proliferation index. However, these markers lack consistent definitions, raising the need for objective criteria. Genome-wide DNA methylation profiles were examined in 136 tumors histologically classified as CN. Clinical/histopathological characteristics were assessed in 93/90 cases, and whole-exome sequencing was conducted in 12 cases. Clinical and molecular characteristics were integrated into a survival model to predict progression-free survival (PFS). A diagnosis of CN was epigenetically confirmed in 125 of 136 cases (92
%K Humans
%K Male
%K Female
%K Neurocytoma: genetics
%K Neurocytoma: pathology
%K Adult
%K Young Adult
%K Brain Neoplasms: genetics
%K Brain Neoplasms: pathology
%K DNA Methylation
%K Middle Aged
%K Adolescent
%K Cohort Studies
%K Neoplasm Recurrence, Local: genetics
%K Prognosis
%K DNA methylation profiling (Other)
%K FGFR3 (Other)
%K Neurocytoma (Other)
%K Progression-free survival (Other)
%K Radiotherapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40498174
%R 10.1007/s00401-025-02894-3
%U https://inrepo02.dkfz.de/record/302003